COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Use of Arimidex and Zoladex as Pretreatment to IVF in Women With Ovarian Endometriosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00286351
Recruitment Status : Completed
First Posted : February 3, 2006
Last Update Posted : April 23, 2007
Information provided by:
Rigshospitalet, Denmark

Brief Summary:
Does a combination of Arimidex and Zoladex make endometriomas shrink and how is the following IVF outcome

Condition or disease Intervention/treatment Phase
Endometriosis Drug: Combined treatment with Arimidex and Zoladex before IVF Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : January 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Endometriosis

Primary Outcome Measures :
  1. size of endometriomas after 2½ month of combined downregulation

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Endometrioma(s)with a size of 20-70 mm, persisted for at least 3 cycles
  • Couples with indication and wish for IVF/ICSI
  • Age of women: 20-40 years
  • Regular menstrual cycle within normal range (21-35 days)
  • Body Mass Index (BMI): 18-30 kg/m2

Exclusion Criteria:

  • History with osteoporosis, liver-, kidney- or heart disease or thromboembolic disease
  • Treatment of endometriosis with GnRH agonist during the last 3 month

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00286351

Layout table for location information
The Fertility Clinic, Copenhagen University Hospital, Rigshospitalet
Copenhagen, Copenhagen East, Denmark, 2100
Sponsors and Collaborators
Rigshospitalet, Denmark
Layout table for investigator information
Principal Investigator: Kristine Lossl, medical doctor The Fertility Clinic, Copenhagen University Hospital Rigshospitalet
Layout table for additonal information Identifier: NCT00286351    
Other Study ID Numbers: endo 220604
First Posted: February 3, 2006    Key Record Dates
Last Update Posted: April 23, 2007
Last Verified: April 2007
Additional relevant MeSH terms:
Layout table for MeSH terms
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs